NO985916L - Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler - Google Patents

Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler

Info

Publication number
NO985916L
NO985916L NO985916A NO985916A NO985916L NO 985916 L NO985916 L NO 985916L NO 985916 A NO985916 A NO 985916A NO 985916 A NO985916 A NO 985916A NO 985916 L NO985916 L NO 985916L
Authority
NO
Norway
Prior art keywords
chelating agents
treatment
metal chelates
free radicals
conditions caused
Prior art date
Application number
NO985916A
Other languages
English (en)
Norwegian (no)
Other versions
NO985916D0 (no
Inventor
Jan Olof Gustav Karlsson
Per Jynge
Robertson Towart
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of NO985916D0 publication Critical patent/NO985916D0/no
Publication of NO985916L publication Critical patent/NO985916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NO985916A 1996-06-24 1998-12-17 Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler NO985916L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (2)

Publication Number Publication Date
NO985916D0 NO985916D0 (no) 1998-12-17
NO985916L true NO985916L (no) 1999-01-25

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
NO985916A NO985916L (no) 1996-06-24 1998-12-17 Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler
NO985917A NO985917L (no) 1996-06-24 1998-12-17 Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO985917A NO985917L (no) 1996-06-24 1998-12-17 Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse

Country Status (14)

Country Link
US (2) US6147094A (enExample)
EP (2) EP0910360B1 (enExample)
JP (2) JP4359651B2 (enExample)
CN (2) CN1228694A (enExample)
AT (2) ATE225178T1 (enExample)
AU (2) AU720570B2 (enExample)
BR (1) BR9709942A (enExample)
CA (2) CA2258299A1 (enExample)
DE (2) DE69716104T2 (enExample)
GB (1) GB9613182D0 (enExample)
IL (1) IL127733A0 (enExample)
NO (2) NO985916L (enExample)
NZ (2) NZ333357A (enExample)
WO (2) WO1997049409A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1770299A (en) 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR20100075503A (ko) 1999-10-01 2010-07-02 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
SI1931321T1 (sl) 2005-08-31 2019-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
US8377969B2 (en) 2007-12-14 2013-02-19 Pledpharma Ab Compounds for use in the treatment of cancer
RU2563825C2 (ru) 2009-07-06 2015-09-20 Пледфарма Аб Фармацевтические композиции и терапевтические способы, в которых применяется комбинация комплексного соединения марганца и соединения в форме, не являющейся марганцевым комплексом
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
ES2683038T3 (es) 2012-01-05 2018-09-24 Pledpharma Ab Calmangafodipir, una nueva entidad química, y otros complejos metálicos mixtos, métodos de preparación, composiciones y métodos de tratamiento
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
BR112015009963A2 (pt) 2012-11-02 2017-07-11 Pledpharma Ab uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
CN106604750B (zh) 2014-06-16 2021-05-07 梅约医学教育与研究基金会 治疗骨髓瘤
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
AU2017238119A1 (en) * 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
CA2259150A1 (en) 1997-12-31
US6147094A (en) 2000-11-14
NO985917L (no) 1999-01-25
AU3268897A (en) 1998-01-14
WO1997049409A1 (en) 1997-12-31
EP0910360B1 (en) 2002-11-27
NZ333315A (en) 2000-07-28
US6258828B1 (en) 2001-07-10
DE69716104T2 (de) 2003-05-28
EP0910360A1 (en) 1999-04-28
NZ333357A (en) 2000-08-25
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
AU720570B2 (en) 2000-06-08
DE69717447D1 (de) 2003-01-09
ATE225178T1 (de) 2002-10-15
JP4162263B2 (ja) 2008-10-08
CN1228694A (zh) 1999-09-15
CA2258299A1 (en) 1997-12-31
WO1997049390A1 (en) 1997-12-31
GB9613182D0 (en) 1996-08-28
AU3268997A (en) 1998-01-14
JP4359651B2 (ja) 2009-11-04
BR9709942A (pt) 1999-08-10
AU720621B2 (en) 2000-06-08
NO985917D0 (no) 1998-12-17
EP0936915B1 (en) 2002-10-02
JP2000513351A (ja) 2000-10-10
NO985916D0 (no) 1998-12-17
CN1228703A (zh) 1999-09-15
DE69717447T2 (de) 2003-09-11
JP2000514044A (ja) 2000-10-24
ATE228361T1 (de) 2002-12-15
IL127733A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
NO985916L (no) Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler
DE69826528D1 (de) Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
EA200000282A1 (ru) Способ введения таксана пациенту, нуждающемуся в лечении таксаном, способ лечения человека таксаном (варианты)
MXPA04004555A (es) Dexrazoxano para tratamiento de cardiotoxicidad inducida por antitumor.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MX9705235A (es) Inhibidores de calpaina y/o catepsina b de oxazolidina substituida.
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
MXPA04000222A (es) Combinaciones para el tratamiento de desordenes inflamatorios.
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
MY136610A (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
YU24403A (sh) Novi retinoidi za terapiju emfizema
MX9601994A (es) Profarmacos de derivados de paclitaxel.
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
ATE485818T1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
DK1124566T3 (da) Ikke-fermenteret osmotisk laxativ til behandling og forebyggelse af colorectale cancere
WO2004033423A3 (en) Anticancer compounds
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
NO20050640L (no) Rutenium anticancer komplekser
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
DE69909636D1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
MXPA03006359A (es) Metodo para tratamiento del cancer.
NO943847L (no) Fremgangsmåte for fremstilling av makrocykliske chelateringsmidler og dannelse av chelater og konjugater derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application